Paolo Moi, Italy. Università di Cagliari Ospedale Pediatrico Microcitemico - A. Cao - CAGLIARI
|
|
- Arnold Garrett
- 6 years ago
- Views:
Transcription
1 T H E O R E T I C A L A N D P R A C T I C A L T R A I N I N G I N HAEMATOLOGICAL RARE DISEASES: from genetic counselling - through bench - to bed Gene Therapy for Hemoglobinopathies Paolo Moi, Italy Università di Cagliari Ospedale Pediatrico Microcitemico - A. Cao - CAGLIARI
2 Timeline gene therapy 1978 Globin gene cloning 1986 LCR discovery 2000 Gene therapy in murin models Th3/ Human gene therapy in XSCID st Gene therapy of human b-thal 2014 Rapid cure b-thal GT 2017 Gene therapy of SCA
3 Current globin gene therapy relies on the insertion of a normal regulated globin gene into a random chromosome b STOP e Gg Ag d b
4 Major progress from use of lentiviral globin vectors LCR e Gg Ag d b HS LTR GAG POL ENV HS b 5 -LTR
5 Vectors are transferred into HSC by ex-vivo gene therapy procedures Transduction with b- globin lentivctors Genetically corrected and compatible HSC Quality controls Mobilization of HSC into peripheral blood of thalassemia patient from Reinfusion Bone marrow reconstitution
6 Objectives of human GT trials Evaluate safety and efficacy of HSC transduced after myeloablation (complete or partial) Evaluate engraftment and BM reconstitution of genetically modified HSCs Evaluate frequency of blood transfusion after GT Safety issues: Absence of clonal dominance and insertional mutagenesis/oncogenesis Absence of RCL (replication competent virl particles)
7 1 st evidence of GT efficacy in humans in USA_France trial (4/10 pz, 2007) Patients 1 e 2 : not treated, reinfusion of backup BM Patient 3: gene transfer in June 2007 ( transfusion independent after 1 year, 10 years follow-up) Patient 4: Gene transfer 50 months before, still transfusion dependent
8 Features of the Lentiglobin vector HPV569 chs4 R-U5-gag Y env cppt RRE b A-T87Q globin gene prom. HS2 HS3 HS4 R-U3 chs4 * chs4 insulators The variant b A-T87Q has double function label vector derived Hb antagonize sickling b A-T87Q
9 Hb g/dl Trial 1 outcome: Hb concentration in pts 3 e b /be b /be Patient n. 3 stably transfusion independent with 2,7 gr di Hb T87Q a 8 yrs of follow-up Patient n. 4 still transfusion dependent with only 0,4 gr di Hb T87Q at 3 years follow up Months post GT HbA T87Q HbF HbE HbA
10 Cloud on the horizon: clonal dominance M Cavazzana-Calvo et al. Nature 467, (2010) doi: /nature09328
11 Insertional mutagensis of the lentivector into the HMGA2 gene HMGA2 250x HMGA x Lentiviral vector LTR LTR mir let7 ex1 ex2 ex3 ex4 ex5 HMGA2 gene
12 % Modified leukocytes HMGA2 dominance reduction with time Months post GT Cells with vector Cells with HMGA2 IS From the 5 th year integration sites of the SPATS2 and ZZEF1 genes outnumber HMGA2 Hb levels constsant after loss of HMGA2 dominance No adverse hematological or clinical effect of the HMGA2 gene in 7 years F-U follow up
13 ( Northstar study HGB-204, 2014) International, multicenter (USA-AUS-THAI), not randomized study, in adults with b-thal major yrs Primary objectives : Efficacy if >2 gr/hbat87q at mesi post GT Safety: absence of RCL, clone dominance, oncogenesis New vector Lentiglobin BB305
14 Vector modifications in study HBG U3-R-U5 gag Y env cppt RRE b-globin gene prom. HS2 HS3 HS4 R-U3 chs4 pa * CMV R-U5-gag Y env cppt RRE b-globin gene prom. HS2 HS3 HS4 R-U3 pa * HPV BB305 Deletion of chs4 insulator Exchange LTRHIV with CMV promoter Improvement of the structure and vector production process
15 Hb g/dl Trial HGB-204: early high production of globin with almost normal Hb levels and transfusion independence in 2/2 pts b /be Months after GT Subject 1: production of 6.7 gr/dl di b A-T87Q a 4,5 months after GT Subject 1: production of 4.2 gr/dl di b A-T87Q a 2 months after GT 6.7 b /be HbA T87Q HbA 2 HbF HbE HbA
16 Hb g/dl Hb fractions (HGB-205): b /be vs b /b b /be Months after GT b /b HbA T87Q HbA 2 HbF HbE HbA
17 Averages post-gt Hgbs at 1 year FU in b-thalassemia patients 4,9 0,2 1 * 5 0,2 1,3 4 4,7 b0/be b0/b0 HbAT87A HbA2 HbF HbE * *
18 10 8 TIGET-btal (Hb gr/dl after GT) b-tal1 (31 M b 39/b+IVS1-110) 6 4 b-tal4 (35 M b 39/b+IVS1-110) b-tal3 (36 F b 39/b+IVS1-110) b-tal5 (14 M b+ivs1 110/b+IVS1-110)
19 Conclusions Efficacy with some dependence from the b- thalassemia genotype Early efficacy of vector BB305 avoids transfusion requirement soon after transplant Same safety profile as autologous transplant with policlonal reconstitution and adverse events no higher than grade 3 The younger the better
20 Conclusions 2 Success linked to complete myeloablation Exceptional results of study 2 ascribed to better vector preparation and to trasduction conditions
21 Future perspectives: genome editing?
22 From random vector integration to gene correction through genome editing and homologous recombination b STOP e Gg Ag d b Cromosoma 11
23 Molecular tools for genome editing Zn FINGER NUCLEASIs (2001) TALEN (2010) CRISPR-CAS9 (2013) PNAs (2016) Normal Mutant Normal DNA NHEJ HDR Paolo Moi - Cagliari
24 CRISPR-Cas9 (Clustered regulatory interspersed palindromic regions- CRISPR associated system 9) The most recent and innovative tool of genome editing Copyright 2014 Elsevier Inc. Terms and Conditions
25 CRISPR/CAS9: a bacterial immune adaptative system
26 The CRISPR/Cas9 system (non homologous end joining, NHEJ) Indel Indel
27 CRISPR/CAS9 Nickase (Homology directed repair, HDR)
28 Reproduction of an HPFH state by CRISPR-CAS9 editing in human cells b-globin locus at 15p15.5 Gg Ag HPFH
29 Homozygous db -Thalassemia Hb: 13.5 gr/dl HbF: 100%
30 Genome-Editing in β-k562 cells CRISPR allin-one vector β-k562 Limiting dilutions 48 h 48 h FACSsorting
31 PCR screening of genome editing events (small indels) Target site Intergenic region Target site G ɣ prom G ɣ A ɣ prom A ɣ 3 amplicons
32 PCR screening of genome editing events (large indels) Target site Intergenic region Target site G ɣ A ɣ G ɣ prom A ɣ prom 3 amplicons G ɣ / A ɣ prom 1 amplicone
33 Expression of g-globin in edited clones g-globin Gg Ag wt H11 H10 H3 G8 G6 E12 D5 C
34 Globin expression of the edited globin genes (western blot) wt wt C1 D5 E12 G6 G8 H3 H10 H11 β-actina g-globina β-globina
35 Delezione omozigote del gene Gg nel clone H3 b d Ag Gg e
36 Deletion in the short arm of chromosome 11 in clone E11
37 Deletion in the short arm of chromosome 11 in clone E11
38 Traslocazione cromosoma 6: 11 nel clone B5
39 Traslocation chrom 6:11 in clone B5
40
CRISPR-mediated Editing of Hematopoietic Stem Cells for the Treatment of β-hemoglobinopathies
CRISPR-mediated Editing of Hematopoietic Stem Cells for the Treatment of β-hemoglobinopathies Jennifer Gori American Society of Gene & Cell Therapy May 11, 2017 editasmedicine.com 1 Highlights Developed
More informationBLUEBIRD BIO, INC. FORM 8-K. (Current report filing) Filed 06/16/14 for the Period Ending 06/14/14
BLUEBIRD BIO, INC. FORM 8-K (Current report filing) Filed 06/16/14 for the Period Ending 06/14/14 Address 60 BINNEY STREET CAMBRIDGE, MA, 02142 Telephone 339-499-9300 CIK 0001293971 Symbol BLUE SIC Code
More informationQuarterly Update & ASH 2017 Abstract Conference Call
Quarterly Update & ASH 2017 Abstract Conference Call November 1, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and
More informationMaking Hope A Reality December 10, Nasdaq : BLUE
Making Hope A Reality December 10, 2014 Nasdaq : BLUE Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words
More informationAn overview of Thalassaemias and Complications
An overview of Thalassaemias and Complications Haemoglobin Haemoglobin is the most abundant protein in blood, and exists as three main types in normal adults: HbA ( ) - 97% HbA 2 ( ) - 2.5% HbF ( ) - 0.5%
More informationNext Generation Sequencing as a tool for breakpoint analysis in rearrangements of the globin-gene clusters
Next Generation Sequencing as a tool for breakpoint analysis in rearrangements of the globin-gene clusters XXXth International Symposium on Technical Innovations in Laboratory Hematology Honolulu, Hawaii
More informationCHAPTER 15. First human gene therapy trial for haemoglobin disorders
IRON2009_CAP.15(390-401):IRON2009 4-12-2009 16:31 Pagina 390 * CHAPTER 15 First human gene therapy trial for haemoglobin disorders Emmanuel Payen, Olivier Nègre, Beatrix Gillet-Legrand, Yves Beuzard, Eliane
More informationThalassemias:general aspects and molecular pathology
Thalassemias:general aspects and molecular pathology Prof. Renzo Galanello Pediatric Clinic 2 University of Cagliari Ospedale Regionale Microcitemie-ASL8 HEMOGLOBINOPATHIES CLASSIFICATION Structurally
More informationGamma gene expression in haemoglobin disorders
Gamma gene expression in haemoglobin disorders Innovative therapies for Red Cell and Iron related disorders EHA / ESH : April 16-18, Cascais, Portugal Swee Lay Thein King s College London School of Medicine
More informationGene Therapy for Sickle Cell Disease: A Safety/Efficacy Trial
Gene Therapy for Sickle Cell Disease: A Safety/Efficacy Trial Elizabeth Hexner A. Introduction Sickle cell disease (SCD) is an autosomal recessive disease of red blood cells (RBCs). A single amino acid
More informationGene therapy of severe β-thalassemia
Gene therapy of severe β-thalassemia Yves Beuzard Thalassemia/ENERCA conference, Madrid, November 2010 yvesbeuzard@yahoo.fr Overview of the Clinical Protocol Autologous transplantation of transduced CD34+
More informationHighly Efficient CRISPR/Cas9 Gene Editing and Long-Term Engraftment of Human Hematopoietic Stem and Progenitor Cells
Highly Efficient CRISPR/Cas9 Gene Editing and Long-Term Engraftment of Human Hematopoietic Stem and Progenitor Cells J. M. Heath, A. Chalishazar, C.S. Lee, W. Selleck, C. Cotta-Ramusino, D. Bumcrot, J.L.
More informationHEMOGLOBIN ELECTROPHORESIS DR ARASH ALGHASI SHAFA HOSPITAL-AHWAZ
HEMOGLOBIN ELECTROPHORESIS DR ARASH ALGHASI SHAFA HOSPITAL-AHWAZ Hemoglobin Hemoglobin (Hb), protein constituting 1/3 of the red blood cells Each red cell has 640 million molecules of Hb sites in the cells:
More informationTherapeutic Genome Editing with CRISPR-Cas and other programmable gene scissors
Brussels, April 12 th 2018 Therapeutic Genome Editing with CRISPR-Cas and other programmable gene scissors Toni Cathomen Gene Therapy returns to Center Stage Engineering the Genome Jameson Golliday (source:
More informationInternational Journal of Drug Research and Technology
Int. J. Drug Res. Tech. 2012, Vol. 2 (7), 472-478 ISSN 2277-1506 International Journal of Drug Research and Technology Available online at http://www.ijdrt.com Original Research Paper SCREENING, ANALYSIS
More informationHaemoglobinopathies case studies 11 th Annual Sickle Cell and Thalassaemia Conference October 2017
Haemoglobinopathies case studies 11 th Annual Sickle Cell and Thalassaemia Conference 11 13 October 2017 Chris Lambert Haematology Service Delivery Manager Viapath Laboratories Kings College Hospital HUMAN
More informationThe Thalassemias in Clinical Practice. Ashutosh Lal, MD Director Comprehensive Thalassemia Program UCSF Benioff Children s Hospital Oakland
The Thalassemias in Clinical Practice Ashutosh Lal, MD Director Comprehensive Thalassemia Program UCSF Benioff Children s Hospital Oakland Outline Thalassemia: definitions and pathophysiology Epidemiology
More informationGenetic Modulation on the Phenotypic Diversity of Sickle Cell Disease
Genetic Modulation on the Phenotypic Diversity of Sickle Cell Disease Malay B. Mukherjee Abstract Sickle cell hemoglobin is a β chain structural variant where valine is substituted for glutamic acid in
More information6.1 Extended family screening
CHAPTER 6 CONCLUSION Cost benefit analysis of thalassemia screening programs have shown that the single years treatment for a β-thalassemia major patient was much higher than a total cost per case prevented.
More informationCan All Thalassemia Patients be Cured? Suradej Hongeng, MD Dept of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University
Can All Thalassemia Patients be Cured? Suradej Hongeng, MD Dept of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University Thalassemia α thalassemia disease Hb bart ( / ) Hb H disease
More informationHigh Hemoglobin F in a Saudi Child Presenting with Pancytopenia
Case Report imedpub Journals http://www.imedpub.com Journal of Pediatric Care ISSN 2471-805X DOI: 10.21767/2471-805X.100002 High Hemoglobin F in a Saudi Child Presenting with Pancytopenia Abstract Saudi
More informationThe hemoglobin disorders are highly prevalent,
NEWER PROGRESS IN GENE THERAPY Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders Derek A. Persons 1 1 Division of Experimental Hematology, Department of Hematology, St. Jude
More informationAnalysis of individual differences in radiosensitivity using genome editing
3 rd International Symposium on the System of Radiological Protection ICRP2015 Analysis of individual differences in radiosensitivity using genome editing Shinya Matsuura Department of Genetics and Cell
More informationClinical Genomics. Ina E. Amarillo, PhD FACMGG
Clinical Genomics Ina E. Amarillo, PhD FACMGG Associate Medical Director, Cytogenetics Lab (CaTG), Lab and Genomic Medicine Assistant Professor, Pathology and Immunology Outline Clinical Genomics Testing
More informationGeorge R. Honig Junius G. Adams III. Human Hemoglobin. Genetics. Springer-Verlag Wien New York
George R. Honig Junius G. Adams III Human Hemoglobin Genetics Springer-Verlag Wien New York George R. Honig, M.D., Ph.D. Professor and Head Department of Pediatrics, College of Medicine University of Illinois
More informationHost Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9
Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9 Kristine E. Yoder, a * and Ralf Bundschuh b a Department of Molecular Virology, Immunology and Medical Genetics, Center
More informationThe diagnosis of Hemoglobinopathies
1ST IFCC, EFLM, AFCB CONFERENCE "LABORATORY MEDICINE: MEETING THE NEEDS OF MEDITERRANEAN NATIONS" Rome, Italy 02/07/2018 The diagnosis of Hemoglobinopathies Dr Antonino Giambona Unit of Hematology of Rare
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationASH 2018 NASDAQ: BLUE 1
ASH 2018 December 3, 2018 NASDAQ: BLUE NASDAQ: BLUE 1 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words
More informationDiagnostic difficulties in prevention and control program for thalassemia in Thailand: atypical thalassemia carriers
Diagnostic difficulties in prevention and control program for thalassemia in Thailand: atypical thalassemia carriers Pranee Winichagoon Fucharoen Thalassemia Research Center Institute of Molecular Biosciences
More informationThalassemia Maria Luz Uy del Rosario, M.D.
Thalassemia Maria Luz Uy del Rosario, M.D. Philippine Society of Hematology and Blood Transfusion Philippine Society of Pediatric Oncology What is Thalassemia Hereditary Hemoglobin disorder Hemolytic anemia
More informationUnraveling Hemoglobinopathies with Capillary Electrophoresis
Session Number 2002 Unraveling Hemoglobinopathies with Capillary Electrophoresis David F. Keren, M.D. Professor of Pathology Division Director, Clinical Pathology The University of Michigan dkeren@med.umich.edu
More informationAnemia s. Troy Lund MSMS PhD MD
Anemia s Troy Lund MSMS PhD MD lundx072@umn.edu Hemoglobinopathy/Anemia IOM take home points. 1. How do we identify the condtion? Smear, CBC Solubility Test (SCD) 2. How does it present clincally? 3. How
More informationJefferies 2015 Global Healthcare Conference Engineering Genetic Cures
Jefferies 2015 Global Healthcare Conference Engineering Genetic Cures Edward Lanphier President and CEO Sangamo BioSciences, Inc. June 1, 2015 Forward Looking Statements This presentation contains forward-looking
More informationVIROLOGY. Engineering Viral Genomes: Retrovirus Vectors
VIROLOGY Engineering Viral Genomes: Retrovirus Vectors Viral vectors Retrovirus replicative cycle Most mammalian retroviruses use trna PRO, trna Lys3, trna Lys1,2 The partially unfolded trna is annealed
More informationRecombinant Protein Expression Retroviral system
Recombinant Protein Expression Retroviral system Viruses Contains genome DNA or RNA Genome encased in a protein coat or capsid. Some viruses have membrane covering protein coat enveloped virus Ø Essential
More informationSupplementary Information. Supplementary Figure 1
Supplementary Information Supplementary Figure 1 1 Supplementary Figure 1. Functional assay of the hcas9-2a-mcherry construct (a) Gene correction of a mutant EGFP reporter cell line mediated by hcas9 or
More informationβ-globin gene transfer to human bone marrow for sickle cell disease
Research article β-globin gene transfer to human bone marrow for sickle cell disease Zulema Romero, 1 Fabrizia Urbinati, 1 Sabine Geiger, 1 Aaron R. Cooper, 2 Jennifer Wherley, 1 Michael L. Kaufman, 1
More informationHAEMATOLOGICAL RARE DISEASES: from genetic counselling - through bench - to bed
Fondazione THEORETICAL AND PRACTICAL TRAINING IN HAEMATOLOGICAL RARE DISEASES: from genetic counselling - through bench - to bed 15-23 September, 2017 CAMPUS OF HEMATOLOGY Franco e Piera Cutino A.O.R.
More informationSICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN
SICKLE CELL DISEASE Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN Objective: The student should be able: To identify the presentation, diagnosis,
More informationSupplementary Information. Novel lentiviral vectors with mutated reverse transcriptase for mrna delivery of TALE nucleases
Supplementary Information Novel lentiviral vectors with mutated reverse transcriptase for mrna delivery of TALE nucleases Ulrike Mock 1, Kristoffer Riecken 1, Belinda Berdien 1, Waseem Qasim 2, Emma Chan
More informationHaemoglobin BY: MUHAMMAD RADWAN WISSAM MUHAMMAD
Haemoglobin BY: MUHAMMAD RADWAN WISSAM MUHAMMAD Introduction is the iron-containing oxygen transport metalloprotein in the red blood cells Hemoglobin in the blood carries oxygen from the respiratory organs
More informationDetecting and Reporting Alpha Thalassemia In Newborns
Detecting and Reporting Alpha Thalassemia In Newborns T. Davis, C. Moore, L. Nayak, M.C. Dorley, M. del Pilar Aguinaga, M. Chan, J. Ubaike, C. Yusuf Alpha Thalassemia Screening Status in the US Clinical
More informationGenetic Modifiers of Sickle Cell Disease Severity. Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University
Genetic Modifiers of Sickle Cell Disease Severity Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University Outline Hb Molecule and Genetic control of globin synthesis Pathophysiology
More informationFebruary 14, 2003 Report on preclinical studies in gc-ko mice Fabio Candotti
February 14, 2003 Report on preclinical studies in gc-ko mice Fabio Candotti Five published reports (see details below) have described the development of peripheral blood lymphocytes as well as cellular
More informationInserm. Gene Therapy of Human beta-thalassemias. Emmanuel Payen Chiang Mai : 2013, March 31
Inserm Gene Therapy of Human beta-thalassemias Emmanuel Payen Chiang Mai : 213, March 31 Institut des Maladies Emergentes et des Thérapies Innovantes (imeti) Service des Thérapies Innovantes (STI) Laboratoire
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/35456 holds various files of this Leiden University dissertation. Author: Hassan, Suha Mustafa Title: Toward prevention of Hemoglobinopathies in Oman Issue
More informationComprehensive Hemoglobin Analysis HBA1/2 (
Comprehensive Hemoglobin Analysis HBA1/2 ( α-globin) and HBB (β-globin) mutation and deletion/duplication analysis and HBD (δ-globin) and HBG1/2 (γ-globin) mutation analysis Description: Hemoglobin (Hb)
More informationThalassemias. Emanuela Veras, M.D. 01/08/2006
Thalassemias Emanuela Veras, M.D. 01/08/2006 Structure and Function of normal Hemoglobin molecules: 2/3 1/3 β: increases from 6 th week of fetal life to 12 months of age At birth: HbF: 75-90% HbA: 10-25%
More informationDr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW
Dr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW Objectives Gain awareness of haemoglobinopathy inheritance, pathophysiology
More informationGenomic structural variation
Genomic structural variation Mario Cáceres The new genomic variation DNA sequence differs across individuals much more than researchers had suspected through structural changes A huge amount of structural
More informationCRISPRaTest Functional dcas9-activator Assay Kit v1 Last update: 2018/07/04 Cellecta, Inc.
CRISPRaTest Functional dcas9-activator Assay Kit v1 Last update: 2018/07/04 Cellecta, Inc. Copyright (c) 2018 Cellecta, Inc. All Rights Reserved. Table of Contents 1. CRISPRaTest Functional dcas9-activator
More informationMaking Hope A Reality bluebird style. January 2018 Nasdaq : BLUE
Making Hope A Reality bluebird style January 2018 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The
More informationThe Medical Genetics Unit
EPIDEMIOLOGY AND PREVENTION OF HAEMOGLOBINOPATHIES Steps needed to move forward in Italy. A professional point of view The Medical Genetics Unit 5 th EUR PEAN SYMP SIUM N RARE ANAEMIAS Ferrara - Castello
More informationThe Challenging Diagnosis of Treacherous Hemoglobinopathies
The Challenging Diagnosis of Treacherous Hemoglobinopathies David F. Keren, M.D. Professor of Pathology The University of Michigan dkeren@med.umich.edu Objectives Use Capillary Electrophoresis and HPLC
More informationMOLECULAR BASIS OF THALASSEMIA IN SLOVENIA
MOLECULAR BASIS OF THALASSEMIA IN SLOVENIA Dijana Plaseska-Karanfilska, MD, PhD Research Centre for Genetic Engineering and Biotechnology Georgi D. Efremov, Macedonian Academy of Sciences and Arts, Skopje,
More informationDisclosures of: Emanuele Angelucci
Company name Novartis Disclosures of: Emanuele Angelucci Research support Employee Consultant Stockholder Speakers bureau Advisory board Chair of TELESTO pro Other EBMT 2012 Educational Session Haemoglobinopathy
More informationChoosing Optimal Viral Vector for T-cell Transduction. Viral vectors for blood cells
Choosing Optimal Viral Vector for T-cell Transduction Max Mamonkin, PhD Center for Cell and Gene Therapy Baylor College of Medicine PACT Webinar Nov 08, 2018 Viral for blood cells Short/long term gene
More informationImproving Outcomes in Sickle Cell Disease: From Targeting Adhesion and Inflammation to Gene Therapy
Improving Outcomes in Sickle Cell Disease: From Targeting Adhesion and Inflammation to Gene Therapy Jorge Ramos Hematology Fellows Conference University of Washington School of Medicine Fred Hutchinson
More informationFunctional validation of cancer susceptibility genes using gene editing
Functional validation of cancer susceptibility genes using gene editing 2-22-2017 Sabine Topka Research Fellow Niehaus Center for Inherited Cancer Genomics www.mskcc.org Inherited Predisposition to Cancer
More informationArticle Preimplantation diagnosis and HLA typing for haemoglobin disorders
RBMOnline - Vol 11. No 3. 2005 362-370 Reproductive BioMedicine Online; www.rbmonline.com/article/1853 on web 20 July 2005 Article Preimplantation diagnosis and HLA typing for haemoglobin disorders Dr
More informationLenti D for adrenoleukodystrophy in boys NIHRIO (HSRIC) ID: 7992 NICE ID: 8732
NIHR Innovation Observatory Evidence Briefing: May 2017 Lenti D for adrenoleukodystrophy in boys NIHRIO (HSRIC) ID: 7992 NICE ID: 8732 LAY SUMMARY Adrenoleukodystrophy (ALD), otherwise known as Lorenzo
More informationExtra Notes 3. Warm. In the core (center) of the body, where the temperature is 37 C.
Extra Notes 3 *The numbers of the slides are according to the last year slides. Slide 33 Autoimmune hemolytic anemia : Abnormal circulating antibodies that target normal antigen on the RBC and cause lysis.
More informationHPLC profile of sickle cell disease in central India
Original Research Article HPLC profile of sickle cell disease in central India Shweta P. Bijwe * Department of Pathology, IGGMC, Nagpur, Maharashtra, India * Corresponding author email: dr.shwetabijwe@gmail.com
More informationFeb 11, Gene Therapy. Sam K.P. Kung Immunology Rm 417 Apotex Center
Gene Therapy Sam K.P. Kung Immunology Rm 417 Apotex Center Objectives: The concept of gene therapy, and an introduction of some of the currently used gene therapy vector Undesirable immune responses to
More informationSupplementary Figure 1. Generation of knockin mice expressing L-selectinN138G. (a) Schematics of the Sellg allele (top), the targeting vector, the
Supplementary Figure 1. Generation of knockin mice expressing L-selectinN138G. (a) Schematics of the Sellg allele (top), the targeting vector, the targeted allele in ES cells, and the mutant allele in
More informationIn adults, the predominant Hb (HbA) molecule has four chains: two α and two β chains. In thalassemias, the synthesis of either the α or the β chains
Thalassaemias Thalassemia Thalassemia is an inherited autosomal recessive blood disease. Associated with absence or reduction in a or b globin chains. Reduced synthesis of one of the globin chains can
More informationCreating transformative gene-based medicines for serious diseases
Creating transformative gene-based medicines for serious diseases Corporate Overview November 2018 1 Forward-Looking Statements The presentation and other related materials may contain a number of forward-looking
More informationAllogeneic hematopoietic stem cell transplantation has been well
REVIEW ARTICLE EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Cure for thalassemia major from allogeneic hematopoietic stem cell transplantation to gene therapy Alok Srivastava 1* and Ramachandran
More informationReport of Beta Thalassemia in Newar Ethnicity
Report of Beta Thalassemia in Newar Ethnicity Rajendra Dev Bhatt 1*, Surendra Koju 2, Prabodh Risal 1 Affiliations: 1 Department of Clinical Biochemistry, Dhulikhel Hospital, Kathmandu University Hospital
More informationSickle cell disease is among the most prevalent inherited monogenic. Gene Therapy in a Patient with Sickle Cell Disease. Brief Report.
The new england journal of medicine Brief Report Gene Therapy in a Patient with Sickle Cell Disease Jean Antoine Ribeil, M.D., Ph.D., Salima Hacein Bey Abina, Pharm.D., Ph.D., Emmanuel Payen, Ph.D., Alessandra
More informationNew technologies for the diagnosis of thalassemia:
New technologies for the diagnosis of thalassemia: Cornelis Harteveld Leiden University Medical Center, The Netherlands ENERCA Ferrara 16 th of November 2013 Introduction to hemoglobinopathies Hb molecule
More information~Lentivirus production~
~Lentivirus production~ May 30, 2008 RNAi core R&D group member Lentivirus Production Session Lentivirus!!! Is it health threatening to lab technician? What s so good about this RNAi library? How to produce
More informationGENETIC FACTORS INFLUENCING HEMOGLOBIN
Southeast Asian J Trop Med Public Health GENETIC FACTORS INFLUENCING HEMOGLOBIN F LEVEL IN β-thalassemia/hb E DISEASE Waraporn Ruangrai and Sumalee Jindadamrongwech Department of Pathology, Faculty of
More informationGenome editing for the therapy of β-haemoglobinopathies
The Cyprus Institute of Neurology and Genetics Genome editing for the therapy of β-haemoglobinopathies Carsten W. Lederer, PhD Molecular Genetics Thalassaemia Department The Cyprus Institute of Neurology
More informationLine Probe Assay for Detection of Alpha Thalassemia: A Pilot Study
Line Probe Assay for Detection of Alpha Thalassemia: A Pilot Study Menon PK *, Nimmakayalu M, Bylappa SK, Kumar M, Abdalhaleem HM Center for Advanced Biomedical Research and Innovation, Gulf Medical University,
More informationThalassemia. By: Rebecca Chang (Period 6)
+ Thalassemia By: Rebecca Chang (Period 6) + Physiology Ø Two types of thalassemia: alpha and beta Ø Autosomal recessive inheritance pattern Ø Hemoglobin is damaged but symptoms greatly vary, especially
More informationAre We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017
Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell Ann Haight, MD 9 Sept 2017 Spoiler alert Yes (we have a cure) And No Work to do! 2 Sickle Cell Treatment Options Supportive Care
More informationThe Prevalence and Heterogeneity of Beta Thalassemia Mutations in The Western Maharashtra Population: A Hospital Based Study
Kamla-Raj 2001 IJHG 1(3): 219-223 (2001) The Prevalence and Heterogeneity of Beta Thalassemia Mutations in The Western Maharashtra Population: A Hospital Based Study S.S. Ambekar, M.A. Phadke, D.N. Balpande,
More informationHAEMATOLOGICAL RARE DISEASES: from genetic counselling - through bench - to bed
Fondazione THEORETICAL AND PRACTICAL TRAINING IN HAEMATOLOGICAL RARE DISEASES: from genetic counselling - through bench - to bed CAMPUS OF HEMATOLOGY Franco e Piera Cutino A.O.R. "Villa Sofia - V. Cervello"
More informationPreface: Thalassemia Bernard G. Forget
Thalassemia Preface: Thalassemia Bernard G. Forget xiii Thalassemia: An Overview of 50 Years of Clinical Research 1005 Vijay G. Sankaran and David G. Nathan The thalassemias are attributable to the defective
More informationEndogenous Retroviral elements in Disease: "PathoGenes" within the human genome.
Endogenous Retroviral elements in Disease: "PathoGenes" within the human genome. H. Perron 1. Geneuro, Geneva, Switzerland 2. Geneuro-Innovation, Lyon-France 3. Université Claude Bernard, Lyon, France
More informationHistocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director
Histocompatibility Evaluations for HSCT at JHMI M. Sue Leffell, PhD Professor of Medicine Laboratory Director JHMI Patient Population Adults Peds NMDP data >20,000 HSCT JHMI HSCT Protocols Bone marrow
More informationEfficient modification of CCR5 in primary human hematopoietic cells using a megatal nuclease and AAV donor template
GENOME EDITING Efficient modification of CCR5 in primary human hematopoietic cells using a megatal nuclease and AAV donor template Blythe D. Sather, 1 * Guillermo S. Romano Ibarra, 1 * Karen Sommer, 1
More informationInserm GENE THERAPY OF HEMOGLOBIN DISORDERS
Inserm GENE THERAPY OF HEMOGLOBIN DISORDERS Institute of Emergent Diseases and Innovative Therapies (imeti) Laboratory of Gene and Cell Therapy (LTGC) CEA, Fontenay aux Roses emmanuel.payen@cea.fr Human
More informationSequencing in Newborn Screening Introduction and Background
Sequencing in Newborn Screening Introduction and Background Suzanne Cordovado, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Centers for Disease Control and Prevention
More informationHEMOLYTIC ANEMIA DUE TO ABNORMAL HEMOGLOBIN SYNTHESIS
Hemolytic Anemia Due to Abnormal Hemoglobin Synthesis MODULE 19 HEMOLYTIC ANEMIA DUE TO ABNORMAL HEMOGLOBIN SYNTHESIS 19.1 INTRODUCTION There are two main mechanisms by which anaemia is produced (a) Thalassemia:
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1: Generation of cetuximab-resistant cells and analysis of singlecell clones. Cetuximab-sensitive cells (LIM1215 and OXCO-2) were chronically treated with cetuximab
More informationNovel Therapeutic Approaches in Sickle Cell Disease
Novel Therapeutic Approaches in Sickle Cell Disease Mark C. Walters, Arthur W. Nienhuis, and Elliott Vichinsky In this update, selected clinical features of sickle cell disease and their management are
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:10.1038/nature11429 S1a 6 7 8 9 Nlrc4 allele S1b Nlrc4 +/+ Nlrc4 +/F Nlrc4 F/F 9 Targeting construct 422 bp 273 bp FRT-neo-gb-PGK-FRT 3x.STOP S1c Nlrc4 +/+ Nlrc4 F/F casp1
More informationA phase I pilot study of safety and feasibility of stem cell therapy for AIDS lymphoma using stem cells treated with a lentivirus vector encoding
A phase I pilot study of safety and feasibility of stem cell therapy for AIDS lymphoma using stem cells treated with a lentivirus vector encoding multiple anti-hiv RNAs John A. Zaia, M.D. John J. Rossi,
More informationChem*3560 Lecture 4: Inherited modifications in hemoglobin
Chem*3560 Lecture 4: Inherited modifications in hemoglobin Genetic modifications fall into two classes: Thalassemias, which are the result of failure to express globin genes. Thalassa is Greek for the
More informationHEMOGLOBINOPATHIES LECTURE OUTLINE. An overview of the structure of hemoglobin. Different types of hemoglobin. Definition of hemoglobinopathies
Slide 1 HEOGLOBINOPATHIES Slide 2 LETURE OUTLINE An overview of the structure of hemoglobin. Different types of hemoglobin. Definition of hemoglobinopathies Sickle ell Disease and Hemoglobin Slide 3 HEOGLOBIN
More informationYour Gene ATG GGT. pd1118 EF1a-ORF, Lenti-ElecD 7803 bp
Mammalian Expression Vectors has mammalian expression vectors suitable for transient or stable expression. These vectors are available with features including various promoters, markers, and fusions. Lentiviral
More informationDr. Ayman Mohsen Mashi, MBBS Consultant Hematology & Blood Transfusion Department Head, Laboratory & Blood Bank King Fahad Central Hospital, Gazan,
Dr. Ayman Mohsen Mashi, MBBS Consultant Hematology & Blood Transfusion Department Head, Laboratory & Blood Bank King Fahad Central Hospital, Gazan, KSA amashi@moh.gov.sa 24/02/2018 β-thalassemia syndromes
More informationCounselling and prenatal diagnosis. Antonis Kattamis, Greece
Counselling and prenatal diagnosis Antonis Kattamis, Greece Epidemiology of Hemoglobinopathies 7% of world population carriers of hemoglobinopathies 500.000 newborns annually affected 300.000 : Thalassemias
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More information